In order to evaluate the effect of interferon (IFN) therapy on titres of antibody to HCV (anti-HCV) we studied prospectively 27 patients included in a randomized controlled clinical trial of IFN given for cryptogenic chronic active liver disease (CALD). In chronic non-A, non-B hepatitis IFN therapy may cause a significant decrease in anti-HCV antibody titres in the majority of the patients with a favourable response to IFN therapy.
Changes of antibody titer to hepatitis C virus during Interferon therapy of cryptogenic chronic active liver disease / G. Diodati, A. Tagger, P. Bonetti, M.L. Ribero, S. Scaccabarozzi, G. Realdi, A. Alberti. ((Intervento presentato al convegno The 1990 International Symposium on Viral Hepatitis and Liver Disease:Contemporary Issues and Future Prospects tenutosi a Houston , Texas nel 1990.
Changes of antibody titer to hepatitis C virus during Interferon therapy of cryptogenic chronic active liver disease
A. TaggerSecondo
;M.L. Ribero;
1990
Abstract
In order to evaluate the effect of interferon (IFN) therapy on titres of antibody to HCV (anti-HCV) we studied prospectively 27 patients included in a randomized controlled clinical trial of IFN given for cryptogenic chronic active liver disease (CALD). In chronic non-A, non-B hepatitis IFN therapy may cause a significant decrease in anti-HCV antibody titres in the majority of the patients with a favourable response to IFN therapy.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
